Literature DB >> 30661922

Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer- A study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO).

Aditi Bhatt1, Snita Sinukumar2, Sanket Mehta3, Dileep Damodaran4, Shabber Zaveri5, Praveen Kammar6, Suniti Mishra7, Loma Parikh8, Rohit Ranade9, Prasanth Penumadu10, Firoz Rajan11.   

Abstract

OBJECTIVES: The goals were to study • The pattern of pathological response to neoadjuvant chemotherapy (NACT) and its clinical implications • The impact of chemotherapy response grade (CRG) on survival
METHODS: A retrospective analysis of patients undergoing interval cytoreductive surgery (CRS) between January 2013 to December 2017 was performed. The surgical and pathological reports were analyzed and surgical and pathological PCI compared. The pathological response to chemotherapy was assessed using the score developed by Bohm. et al.
RESULTS: In 79 patients, it was observed that sites involved by disease first like ovaries and pelvic peritoneum (lower region) were the last to respond preceded by the omentum, right upper quadrant (RUQ) peritoneum (upper region) and parietal peritoneum (middle region). Microscopic residual disease was seen in 20.2% in normal looking areas of peritoneum and in 20% with no gross residual disease in the RUQ. Visual inspection during surgery overestimated the disease extent in 40.5% and underestimated it in 15.1%. There was no difference in the progression free (p = 0.587) and overall survival (p = 0.157) between patients with CRG 1, 2 and 3 (poor, moderate, and complete/near complete response, respectively). Retroperitoneal nodes were positive in 0% with CRG 3, 27.5% with CRG 2 and 72.7% with CRG 1 (p < 0.0001).
CONCLUSIONS: The pathological response to NACT follows a specific pattern. Visual inspection is of limited value in assessing disease extent following NACT. Surgery following NACT should target sites involved before NACT and not just residual disease. The response in regional nodes should be included in chemotherapy response scores.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Advanced ovarian cancer; Interval cytoreductive surgery; Interval debulking; Pathological response; Total parietal peritonectomy

Mesh:

Year:  2019        PMID: 30661922     DOI: 10.1016/j.ejso.2019.01.009

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  2 in total

1.  Total Parietal Peritonectomy Can Be Performed with Acceptable Morbidity for Patients with Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: Results From a Prospective Multi-centric Study.

Authors:  Aditi Bhatt; Praveen Kammar; Snita Sinukumar; Loma Parikh; Nutan Jumle; Sakina Shaikh; Sanket Mehta
Journal:  Ann Surg Oncol       Date:  2020-08-03       Impact factor: 5.344

2.  Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer.

Authors:  Aditi Bhatt; Snita Sinukumar; Vahan Kepenekian; Praveen Kammar; Sanket Mehta; Sakina Shaikh; Witold Gertych; Naoual Bakrin; Olivier Glehen
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.